This clinical trial is focused on studying the effects of a medication called on individuals with . Anorexia nervosa is a condition characterized by an intense fear of gaining weight and a distorted body image, leading to restricted food intake and excessive weight loss. The study aims to evaluate how donepezil, which is an , can help improve the symptoms associated with anorexia nervosa. Donepezil is commonly used to treat symptoms of Alzheimer’s disease by increasing the levels of a chemical in the brain that is important for memory and learning.

Participants in the study will receive either donepezil or a , which looks like the medication but does not contain the active ingredient. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are not influenced by expectations. The treatment will be administered orally, and the study will last for a period of three months, during which participants will be monitored for changes in their symptoms and overall health.

The primary goal of the study is to observe any improvements in the symptoms of anorexia nervosa, such as changes in eating habits and body image perception. Additionally, the study will track other health indicators, including body mass index and psychological assessments, to gather comprehensive data on the effects of donepezil. Participants will undergo various tests and assessments at different points throughout the study to measure these changes. The study will also monitor for any potential side effects or adverse reactions to the medication. The findings from this trial could provide valuable insights into new treatment options for individuals with anorexia nervosa.